Abstracts tagged "Abstracts"

Abstract Number: 051 • 2023 Pediatric Rheumatology Symposium
Juvenile Relapsing Polychondritis: A Single Center Cohort
Angela Chun¹, Sarah Molina¹, Marietta De Guzman² and Maria Pereira Palacios¹, ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Relapsing polychondritis (RPC) is a rare multisystemic autoimmune disease associated with recurrent, progressive inflammation in cartilaginous structures. In children, the most common manifestations are…
Abstract Number: L04 • 2019 ACR/ARP Annual Meeting
Cardiovascular Disease Risk in Calcium Pyrophosphate Deposition Disease
Maaman Bashir¹, Katherine Sherman ², Sara K. Tedeschi ³ and Ann Rosenthal ¹, ¹Medical College of Wisconsin, Milwaukee, ²Milwaukee VAMC, Milwaukee, ³Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease results from precipitation of calcium pyrophosphate (CPP) crystals in joints. Prior studies demonstrated that vascular calcification is more common…
Abstract Number: 1319 • 2019 ACR/ARP Annual Meeting
Impact of ACL Injury Management on the Development of Knee Osteoarthritis: A Meta-analysis
stéphanie Ferrero¹, marion louvois ¹, Thomas Barnetche ², Thao Pham ³, Véronique Breuil ¹ and christian roux ⁴, ¹University of Nice, nice, France, ²FHU ACRONIM, Department of Rheumatology, Centre Hospitalier Universitaire, Bordeaux, France, Bordeaux, France, ³Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, France, ⁴CHU Pasteur Nice, Nice, France
Background/Purpose: Background: The development of knee's osteoarthritis after anterior cruciate ligament ACL injury is now widely recognized. The impact of surgical or rehabilitative management on…
Abstract Number: 1744 • 2019 ACR/ARP Annual Meeting
Serum Sickness Following Rituximab Treatment of Childhood-Onset SLE: A Single Center Experience
Ugo Awa¹, Marietta De Guzman ² and Eyal Muscal ³, ¹Baylor College of Medicine/Texas Children's Hospital, Houston, ²Baylor College of Medicine/Texas Children's Hospital, Houston, TX, ³Baylor College of Medicine, Houston, TX
Background/Purpose: Childhood-onset SLE (cSLE) is an autoimmune disease characterized by multiorgan involvement often necessitating a variety of immunolytic and immunomodulatory therapies to achieve adequate disease…
Abstract Number: PP11 • 2018 ACR/ARHP Annual Meeting
The Road Less Traveled– Nontraditional Approaches to Increased Patient Adherence and Positive Outcomes
Carlene Harrison, AstraZeneca, Gaithersburg, MD
Background/Diagnosis: African-American female diagnosed with SLE, Lupus Nephritis, Discoid Lupus, and Raynaud’s Phenomenon in 2011. Symptoms included joint pain, edema in the ankles, malar rash,…
Abstract Number: 2226 • 2012 ACR/ARHP Annual Meeting
Application of Classification Criteria for Psoriatic Arthritis to Patients of the Rotterdam Early Arthritis Cohort
Jos Van der Kaap¹, Johanna M.W. Hazes², M. Vis³, Ilya Tchetverikov⁴ and Jolanda J. Luime², ¹Rotterdam, Netherlands, ²Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ³Rheumatology, VU University medical center, Amsterdam, Netherlands, ⁴Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands
Background/Purpose: Psoriatic arthritis (PsA) poses a diagnostic challenge due to lack of a clear case definition. This has led to varying reports on prevalence, which…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].